Molecular mechanisms underlying the beneficial effects of Urocortin 2 in pulmonary arterial hypertension

被引：0
|
作者：
Maia-Rocha, C. [1 ]
Adao, R. [1 ]
Mendes-Ferreira, P. [1 ]
Santos-Ribeiro, D. [1 ]
Rademaker, M. [2 ]
Leite-Moreira, A. F. [1 ]
Bras-Silva, C. [1 ]
机构：
[1] Univ Porto, Dept Physiol & Cardiothorac Surg, Fac Med, Oporto, Portugal
[2] Univ Otago Christchurch, Christchurch Heart Inst, Dept Med, Christchurch, New Zealand
来源：
CARDIOVASCULAR RESEARCH | 2016年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
424
引用
收藏
页码：S75 / S76
页数：2
相关论文
共 50 条
  • [31] Oxygen and pulmonary arterial hypertension: effects, mechanisms, and therapeutic benefits
    Green, Simon
    Stuart, Deidre
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (01) : 127 - 136
  • [32] Unsolved Issues on Beneficial Effects of Combination Therapy With Sotatercept in Pulmonary Arterial Hypertension
    Benincasa, Giuditta
    Strozziero, Maria Grazia
    Trama, Ugo
    Napoli, Claudio
    HEART LUNG AND CIRCULATION, 2024, 33 (01): : 12 - 13
  • [33] Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension
    Adao, Rui
    Mendes-Ferreira, Pedro
    Santos-Ribeiro, Diana
    Maia-Rocha, Carolina
    Pimentel, Luis
    Pinto, Claudia
    Mulvaney, Eamon P.
    Reid, Helen M.
    Kinsella, B. Therese
    Potus, Francois
    Breuils-Bonnet, Sandra
    Rademaker, Miriam T.
    Provencher, Steeve
    Bonnet, Sebastien
    Leite-Moreira, Adelino
    Bras-Silva, Carmen
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [34] Molecular Mechanisms Underlying the Beneficial Effects of Exercise on Brain Function and Neurological Disorders
    Nay, Kevin
    Smiles, William J.
    Kaiser, Jacqueline
    McAloon, Luke M.
    Loh, Kim
    Galic, Sandra
    Oakhill, Jonathan S.
    Gundlach, Andrew L.
    Scott, John W.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (08)
  • [35] Untargeted metabolomics towards understanding molecular mechanisms of pulmonary arterial hypertension
    Wawrzyniak, R.
    Dabrowska-Kugacka, A.
    Macioszek, S.
    Gockowska, I.
    Biesemans, M.
    Furga, A.
    Zieba, B.
    Lewicka, E.
    Markuszewski, M.
    EUROPEAN HEART JOURNAL, 2021, 42 : 3421 - 3421
  • [36] Novel Molecular Mechanisms Involved in the Medical Treatment of Pulmonary Arterial Hypertension
    Martin de Miguel, Irene
    Cruz-Utrilla, Alejandro
    Oliver, Eduardo
    Escribano-Subias, Pilar
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [37] Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension
    Adao, R.
    Mendes-Ferreira, P.
    Maia-Rocha, C.
    Santos-Ribeiro, D.
    Potus, F.
    Breuils-Bonnet, S.
    Provencher, S.
    Bonnet, S.
    Rademaker, M.
    Leite-Moreira, A. F.
    Bras-Silva, C.
    CARDIOVASCULAR RESEARCH, 2016, 111 : S114 - S114
  • [38] Pathogenic mechanisms of pulmonary arterial hypertension
    Chan, Stephen Y.
    Loscalzo, Joseph
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2008, 44 (01) : 14 - 30
  • [39] Mechanisms of disease: Pulmonary arterial hypertension
    Farber, HW
    Loscalzo, J
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (16): : 1655 - 1665
  • [40] Mechanisms of disease: pulmonary arterial hypertension
    Schermuly, Ralph T.
    Ghofrani, Hossein A.
    Wilkins, Martin R.
    Grimminger, Friedrich
    NATURE REVIEWS CARDIOLOGY, 2011, 8 (08) : 443 - 455
12345